What question did this study set out to answer?

To investigate the therapeutic potential of Lp-PLA2 inhibition in MYC-driven osteosarcoma.

Abstract 3059: Targeting metabolic dependencies in MYC-driven osteosarcoma through Lp-PLA2 inhibition

View Full Paper

Ask AI

Bookmark

Authors

Demonstrates the efficacy of Lp-PLA2 inhibition in reducing tumor size in MYC-driven osteosarcoma, suggesting a potential new treatment avenue.

To investigate the therapeutic potential of Lp-PLA2 inhibition in MYC-driven osteosarcoma.
Conducted high-throughput screening of 2,036 compounds on MYC-high patient-derived xenograft OS cell line.
Evaluated Darapladib's efficacy in 2D and 3D models through IC50 determination.
Assessed cell viability, migration, and spheroid formation post-treatment.
Tested in vivo efficacy in NSG mice using high MYC-expressing PDX models.
Darapladib exhibited IC50 values below 5 μM in both PDX and murine OS models.
Treatment led to significant reduction in spheroid size and impaired migration.
In vivo studies showed decreased average primary tumor volume in high MYC models.
Low-MYC expressing lines had higher IC50 values compared to high-MYC lines.

Shelmidine et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Demonstrates the efficacy of Lp-PLA2 inhibition in reducing tumor size in MYC-driven osteosarcoma, suggesting a potential new treatment avenue.

To investigate the therapeutic potential of Lp-PLA2 inhibition in MYC-driven osteosarcoma.
Conducted high-throughput screening of 2,036 compounds on MYC-high patient-derived xenograft OS cell line.
Evaluated Darapladib's efficacy in 2D and 3D models through IC50 determination.
Assessed cell viability, migration, and spheroid formation post-treatment.
Tested in vivo efficacy in NSG mice using high MYC-expressing PDX models.
Darapladib exhibited IC50 values below 5 μM in both PDX and murine OS models.
Treatment led to significant reduction in spheroid size and impaired migration.
In vivo studies showed decreased average primary tumor volume in high MYC models.
Low-MYC expressing lines had higher IC50 values compared to high-MYC lines.

Shelmidine et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark